-
Mashup Score: 0‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis - 6 month(s) ago
SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.“Secukinumab in subcutaneous injection form is already approved for the treatment of the entire spectrum of axial spondyloarthritis — radiographic,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 11FDA Approves Secukinumab for Hidradenitis Suppurativa - 6 month(s) ago
Secukinumab is currently the only anti-interleukin (IL)-17A inhibitor approved for the condition.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0Philip Mease, MD: Secukinumab Approval Expands Treatment Options for Rheumatic Disease - 7 month(s) ago
The approval of the intravenous formulation of secukinumab allows healthcare providers to better tailor treatment to their patients’ unique needs.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
The approval of the intravenous formulation of #secukinumab allows healthcare providers to tailor treatment to their patients’ unique needs. https://t.co/K2zp3WzDPc #PsoriaticArthritis
-
-
Mashup Score: 0Secukinumab Significantly Improves Hindradenitis Suppurativa Regardless of Demographics - 10 month(s) ago
A post hoc analysis of phase 3 adds support to the IL-17A inhibitor for the potential treatment of HS.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Secukinumab Demonstrates Safety, Efficacy in Patients with Ankylosing Spondylitis, Psoriatic Arthritis - 1 year(s) ago
Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving secukinumab.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving secukinumab.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Alexa Kimball, MD, MPH: Latest Trial Data on Secukinumab for Hidradenitis Suppurativa - 1 year(s) ago
A recent interview with Alexa Kimball, MD, MPH, regarding recent data from the SUNRISE and SUNSHINE studies on secukinumab for HS patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Newly released safety and efficacy data on Novartis’ secukinumab for hidradenitis suppurativa is published in The Lancet.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
An IV formulation of #secukinumab met all primary efficacy endpoints in patients with axial spondyloarthritis over 52 weeks. 🗨️"I always like medicines, including biologics, that have dose flexibility." - Dr Atul Deodhar @OHSUNews 👇 Read more https://t.co/Ow6SKyQVVS